Warfarin Study with MSM and Iverson Genetics Receives CMS Approval
Morehouse School of Medicine (MSM) and Iverson Genetic Diagnostics recently announced that its WARFARIN Clinical Study has received approval from the Centers for Medicare & Medicaid Services (CMS). The two-year study will assess the impact of genetic information in calculating doses and the changes in the rate of adverse events when initiating Warfarin drug therapy. MSM is an ACTSI partner. Read more…